Published in Proc Natl Acad Sci U S A on September 11, 2001
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | NCT00542191
Analysis of Brain Metastasis in Patients With Lung Cancer | NCT00071344
Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes | NCT04403984
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A (2002) 9.83
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Coexpression analysis of human genes across many microarray data sets. Genome Res (2004) 9.38
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol (2004) 7.68
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res (2008) 7.65
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol (2008) 7.18
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Cells of origin in cancer. Nature (2011) 6.85
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A (2006) 6.26
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell (2014) 5.52
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature (2009) 5.32
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol (2004) 5.29
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
The human keratins: biology and pathology. Histochem Cell Biol (2008) 5.13
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A (2003) 4.69
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med (2011) 4.47
Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. Nucleic Acids Res (2004) 4.43
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 4.31
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev (2009) 4.29
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol (2003) 4.24
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet (2006) 3.96
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Regularized Multivariate Regression for Identifying Master Predictors with Application to Integrative Genomics Study of Breast Cancer. Ann Appl Stat (2010) 3.94
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer (2011) 3.85
Gastric adenocarcinoma: review and considerations for future directions. Ann Surg (2005) 3.83
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol (2010) 3.79
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell (2004) 3.73
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics (2005) 3.66
Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63
Choosing the right cell line for breast cancer research. Breast Cancer Res (2011) 3.57
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med (2010) 3.43
How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst (2014) 3.43
Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics (2006) 3.40
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Molecular portraits of human breast tumours. Nature (2000) 94.14
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res (2001) 6.78
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer (1995) 4.59
The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer (1983) 4.33
Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol (1996) 4.11
The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer (1986) 4.11
Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta (1997) 3.93
Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol (1988) 3.92
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Molecular portraits of human breast tumours. Nature (2000) 94.14
Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 88.48
Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics (1989) 79.44
Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet (1980) 75.25
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet (2001) 63.36
Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol Biol Cell (1998) 62.20
Exploring the metabolic and genetic control of gene expression on a genomic scale. Science (1997) 60.15
The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res (2004) 54.37
The transcriptional program of sporulation in budding yeast. Science (1998) 37.23
Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell (2000) 36.09
Two differentially regulated mRNAs with different 5' ends encode secreted with intracellular forms of yeast invertase. Cell (1982) 25.10
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A (1996) 24.18
A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res (1996) 23.16
Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. Nature (2001) 21.55
Genetic and physical maps of Saccharomyces cerevisiae. Nature (1997) 21.48
Missing value estimation methods for DNA microarrays. Bioinformatics (2001) 20.84
Genetic engineering in vivo using translocatable drug-resistance elements. New methods in bacterial genetics. J Mol Biol (1977) 20.29
SGD: Saccharomyces Genome Database. Nucleic Acids Res (1998) 20.26
A Saccharomyces cerevisiae genomic plasmid bank based on a centromere-containing shuttle vector. Gene (1987) 19.68
Sterile host yeasts (SHY): a eukaryotic system of biological containment for recombinant DNA experiments. Gene (1979) 19.39
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Exploring the new world of the genome with DNA microarrays. Nat Genet (1999) 19.05
Integrating functional genomic information into the Saccharomyces genome database. Nucleic Acids Res (2000) 18.52
Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A (2000) 18.42
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
A common language for physical mapping of the human genome. Science (1989) 17.36
Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet (1996) 15.73
Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet (1999) 14.96
Monolithic microfabricated valves and pumps by multilayer soft lithography. Science (2000) 14.37
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Using the Saccharomyces Genome Database (SGD) for analysis of protein similarities and structure. Nucleic Acids Res (1999) 13.65
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
Promoter-specific binding of Rap1 revealed by genome-wide maps of protein-DNA association. Nat Genet (2001) 13.05
DNA arrays for analysis of gene expression. Methods Enzymol (1999) 12.50
Gene expression informatics--it's all in your mine. Nat Genet (1999) 12.35
Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. Science (1987) 12.20
Mutagenesis by insertion of a drug-resistance element carrying an inverted repetition. J Mol Biol (1975) 11.14
A working guide to boosted regression trees. J Anim Ecol (2008) 10.90
Correct integration of retroviral DNA in vitro. Cell (1987) 10.73
Structure and function of the yeast URA3 gene: expression in Escherichia coli. Gene (1984) 10.07
Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med (1998) 9.72
Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms. Proc Natl Acad Sci U S A (1986) 9.51
A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev (1989) 8.80
Phenotypic analysis of temperature-sensitive yeast actin mutants. Cell (1985) 8.53
Mapping complex genetic traits in humans: new methods using a complete RFLP linkage map. Cold Spring Harb Symp Quant Biol (1986) 8.22
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Gaussian models for genetic linkage analysis using complete high-resolution maps of identity by descent. Am J Hum Genet (1993) 8.05
The Stanford Microarray Database. Nucleic Acids Res (2001) 7.77
Integration of murine leukemia virus DNA depends on mitosis. EMBO J (1993) 7.62
The yeast GTP-binding YPT1 protein and a mammalian counterpart are associated with the secretion machinery. Cell (1988) 7.39
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32